The Push to Grow BD Medical Devices
Becton Dickinson's strength in medical devices has always been building large market shares in high volume lines and then managing for profitability through more efficient manufacturing. But the company has begun an aggressive growth campaign just as its core businesses have begun to stagnate. Customer consolidation and more aggressive competition is leading this cautious company to become a risk-taker.
You may also be interested in...
Drug manufacturing in the EU would grind to a halt in under three years if a proposal to restrict per- and polyfluoroalkyl substances in the European Economic Area is implemented in its current form, says industry group EFPIA.
Users of the new catalogs will benefit from a modern technology with enhanced view, search, export and data submission functionalities, says the European Commission.
Despite winning a landmark multi-billion-dollar antitrust suit earlier this year, Gilead Sciences has seen a US court give an initial green light allowing it to shell out nearly $250m to settle antitrust claims from direct purchasers of its two major HIV drugs.